Splash Beverage Group (SBEV) entered a licensing agreement with Argent BioPharma (RGT) for CannEpil, a cannabinoid-based therapy targeting drug-resistant epilepsy. The announcement provides limited financial detail, implying modest immediate impact absent further clinical/regulatory milestones.
Splash Beverage Group (SBEV) entered a licensing agreement with Argent BioPharma (RGT) for CannEpil, a cannabinoid-based therapy targeting drug-resistant epilepsy. The announcement provides limited financial detail, implying modest immediate impact absent further clinical/regulatory milestones.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
